皮肤免疫相关不良事件的预防与管理:EADV工作组声明
该EADV工作组声明聚焦癌症免疫治疗(尤其免疫检查点抑制剂)所致皮肤免疫相关不良事件(cirAEs),涵盖从轻度皮疹到中毒性表皮坏死松解症等严重情况。文章旨在探讨和分析cirAEs的预防措施,提出通过识别危险因素、早期识别征象和实施预防策略,可减轻irAEs严重程度并改善患者结局与生活质量。
要点
- 免疫检查点抑制剂可引发皮肤irAEs,严重者可危及生命。
- 识别危险因素与早期征象是预防cirAEs的关键环节。
- 实施预防策略有助于降低irAEs严重程度、改善患者结局。
核心结论
- 通过识别危险因素、早期识别征象和实施预防策略,医疗专业人员可显著减轻irAEs的严重程度,从而改善患者结局与生活质量。
研究设计与样本
- EADV工作组声明,旨在探讨和分析皮肤免疫相关不良事件(cirAEs)的预防措施。
主要发现
- 免疫治疗可能诱发免疫相关不良事件(irAEs),包括皮肤事件,范围从轻度皮疹到中毒性表皮坏死松解症等严重危及生命的状况。
临床怎么用
- 医疗专业人员应识别cirAEs危险因素、早期识别征象并实施预防策略,以减轻irAEs严重程度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cancer immunotherapy, particularly immune checkpoint inhibitors (ICI), has revolutionized oncology treatment by leveraging the immune system to recognize and eliminate cancer cells. However, despite its efficacy, immunotherapy may induce immune-related adverse events (irAEs), including dermatological events, that can range from mild rashes to severe life-threatening conditions such as toxic epidermal necrolysis. This paper aims to explore and analyse the preventive measures for cutaneous irAEs (cirAEs). By identifying risk factors, recognizing early signs and implementing preventive strategies, healthcare professionals can significantly mitigate the severity of irAEs, thereby improving patient outcomes and quality of life.
引用
- Fattore D, Apalla Z, Freites-Martinez A, et al. Prevention and management of cutaneous immune-related adverse events: EADV Task Force statement. J Eur Acad Dermatol Venereol. 2025. PMID: 41165224. doi:10.1111/jdv.70149
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。